Therapy Detail

Therapy Name Durvalumab + Oleclumab
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Durvalumab Imfinzi MEDI4736 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer (FDA.gov).
Oleclumab MEDI9447 CD73 Antibody 6 Immune Checkpoint Inhibitor 99 Oleclumab (MEDI9447) is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 27622077).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03822351 Phase II Durvalumab Durvalumab + IPH2201 Durvalumab + Oleclumab Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) Recruiting
NCT03794544 Phase II Durvalumab + Oleclumab AZD9150 + Durvalumab Durvalumab Durvalumab + IPH2201 Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Not yet recruiting
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Recruiting
NCT03773666 Phase I Durvalumab + Oleclumab Durvalumab A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Recruiting